Heron Therapeutics (NASDAQ: HRTX) announced that data from Heron’s recently completed MAGIC Study of SUSTOL (granisetron) Injection, extended release, for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA

Brean Capital Raises Price Target on Heron Therapeutics (HRTX) Following Positive HTX-011 Results September 23, 2015 11:00 AM Heron Therapeutics (HRTX) PT Lifted to $58 at Jefferies Following Positive DataSeptember 23, 2015 6:46 AM Heron Therapeutics to Present Data From Completed Phase 3 MAGIC Study of SUSTOL® at ASCO Breast Cancer SymposiumSeptember 22, 2015 8:01 AM